Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8012) 8012
Publication (532) 532
Book Review (84) 84
Book / eBook (77) 77
Book Chapter (31) 31
Conference Proceeding (18) 18
Magazine Article (18) 18
Newsletter (16) 16
Dissertation (4) 4
Newspaper Article (4) 4
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6659) 6659
male (4937) 4937
schizophrenia - drug therapy (4267) 4267
schizophrenia (4261) 4261
female (3816) 3816
antipsychotic agents - adverse effects (3794) 3794
psychiatry (3782) 3782
adult (3618) 3618
index medicus (2594) 2594
antipsychotic agents - therapeutic use (2367) 2367
middle aged (2321) 2321
pharmacology & pharmacy (1859) 1859
animals (1644) 1644
neurosciences (1630) 1630
clozapine - adverse effects (1130) 1130
rats (960) 960
clozapine (947) 947
adolescent (915) 915
dose-response relationship, drug (883) 883
schizophrenic psychology (875) 875
olanzapine (837) 837
basal ganglia diseases - chemically induced (833) 833
risk factors (828) 828
clinical neurology (820) 820
aged (795) 795
schizophrenia - chemically induced (781) 781
clozapine - therapeutic use (731) 731
antipsychotic agents - administration & dosage (709) 709
risperidone (704) 704
treatment outcome (653) 653
disease models, animal (639) 639
psychotic disorders - drug therapy (594) 594
antipsychotics (593) 593
antipsychotic drugs (581) 581
risperidone - adverse effects (569) 569
haloperidol (554) 554
psychiatric status rating scales (554) 554
schizophrenia - complications (539) 539
mice (536) 536
atypical antipsychotics (509) 509
schizophrenia - physiopathology (487) 487
antipsychotic agents - pharmacology (470) 470
young adult (468) 468
time factors (466) 466
schizophrenia - diagnosis (465) 465
dopamine (455) 455
double-blind (444) 444
mental disorders (440) 440
benzodiazepines - adverse effects (430) 430
analysis (428) 428
drug therapy, combination (427) 427
risk (423) 423
schizophrenia, paranoid - drug therapy (422) 422
drugs (421) 421
psychology, clinical (419) 419
double-blind method (408) 408
risperidone - therapeutic use (408) 408
brain (391) 391
rats, sprague-dawley (388) 388
psychosis (382) 382
prevalence (379) 379
schizophrenia - metabolism (378) 378
drug therapy (361) 361
haloperidol - adverse effects (360) 360
weight gain - drug effects (356) 356
schizophrenia - blood (350) 350
psychotropic drugs (341) 341
chronic disease (333) 333
research (333) 333
obesity - chemically induced (331) 331
aripiprazole (319) 319
drug administration schedule (318) 318
behavior, animal - drug effects (314) 314
prefrontal cortex (309) 309
pregnancy (308) 308
article (301) 301
bipolar disorder - drug therapy (298) 298
motor activity - drug effects (298) 298
haloperidol - therapeutic use (296) 296
neuroleptics (296) 296
schizophrenia - epidemiology (295) 295
clinical trials as topic (292) 292
piperazines - adverse effects (289) 289
benzodiazepines - therapeutic use (282) 282
brain - drug effects (275) 275
bipolar disorder (271) 271
retrospective studies (270) 270
follow-up studies (264) 264
piperazines - therapeutic use (264) 264
quetiapine fumarate (262) 262
hyperprolactinemia - chemically induced (260) 260
age factors (257) 257
complications and side effects (256) 256
care and treatment (253) 253
cognition disorders - chemically induced (253) 253
benzodiazepines (250) 250
parkinson disease, secondary - chemically induced (247) 247
phencyclidine (245) 245
body mass index (244) 244
prolactin - blood (242) 242
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (62) 62
UofT at Mississauga - Stacks (16) 16
OISE - Stacks (7) 7
St. Michael's College (John M. Kelly) - 2nd Floor (4) 4
UofT at Scarborough - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Robarts - Stacks (3) 3
Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Gerstein Science - Missing (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Knox College (Caven) - Stacks (2) 2
Victoria University E.J. Pratt - Stacks (2) 2
Credit Valley Hospital - Reserve desk (1) 1
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Humber River Regional Hospital - Online (1) 1
Markham Stouffville Hospital - Stacks (1) 1
OISE - Reference (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - General (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Chaplain Dept. (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Reserve desk (1) 1
Trillium Health Centre - Stacks (1) 1
UofT at Scarborough - Withdrawn (1) 1
West Park Healthcare Centre - Hospital Department (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7513) 7513
German (206) 206
French (124) 124
Russian (66) 66
Polish (39) 39
Japanese (34) 34
Spanish (29) 29
Dutch (28) 28
Chinese (19) 19
Swedish (15) 15
Hungarian (14) 14
Portuguese (13) 13
Danish (12) 12
Italian (8) 8
Czech (7) 7
Finnish (5) 5
Norwegian (5) 5
Hebrew (4) 4
Romanian (3) 3
Turkish (3) 3
Afrikaans (1) 1
Korean (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?
by Hall, Wayne
Addiction, ISSN 0965-2140, 01/2015, Volume 110, Issue 1, pp. 19 - 35
Aims To examine changes in the evidence on the adverse health effects of cannabis since 1993. Methods A comparison of the evidence in 1993 with the evidence... 
epidemiology | dependence | Cannabis | health risks | drug‐related harms | mental health | Drug-related harms | Epidemiology | Dependence | Health risks | Mental health | SUBSTANCE USE | PSYCHOSOCIAL ADJUSTMENT | drug-related harms | PSYCHIATRY | ILLICIT DRUG-USE | PULMONARY-FUNCTION | SUBSTANCE ABUSE | MENTAL-HEALTH | LUNG-CANCER | TESTING HYPOTHESES | PSYCHOTIC SYMPTOMS | PRENATAL MARIJUANA EXPOSURE | USE DISORDERS | Prenatal Exposure Delayed Effects - epidemiology | Cognition Disorders - chemically induced | Humans | Marijuana Abuse - etiology | Educational Status | Brain Diseases - chemically induced | Neoplasms - chemically induced | Cardiovascular Diseases - epidemiology | Female | Marijuana Abuse - epidemiology | Marijuana Smoking - adverse effects | Schizophrenia - chemically induced | Brain Diseases - epidemiology | Abnormalities, Drug-Induced - epidemiology | Fetal Development - drug effects | Risk Factors | Respiratory Tract Diseases - chemically induced | Psychotic Disorders - epidemiology | Street Drugs - adverse effects | Prenatal Exposure Delayed Effects - etiology | Schizophrenia - epidemiology | Psychoses, Substance-Induced - epidemiology | Pregnancy | Automobile Driving - statistics & numerical data | Respiratory Tract Diseases - epidemiology | Abnormalities, Drug-Induced - etiology | Accidents, Traffic - statistics & numerical data | Psychoses, Substance-Induced - etiology | Cardiovascular Diseases - chemically induced | Cognition Disorders - epidemiology | Neoplasms - epidemiology | Psychotic Disorders - etiology | Marijuana | Health aspects | Medical research | Drug addiction
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Physical Health Monitoring of Patients With Schizophrenia
by Marder, Stephen R and Essock, Susan M and Miller, Alexander L and Buchanan, Robert W and Casey, Daniel E and Davis, John M and Kane, John M and Lieberman, Jeffrey A and Schooler, Nina R and Covell, Nancy and Stroup, Scott and Weissman, Ellen M and Wirshing, Donna A and Hall, Catherine S and Pogach, Leonard and Pi-Sunyer, Xavier and Bigger, J. Thomas and Friedman, Alan and Kleinberg, David and Yevich, Steven J and Davis, Bonnie and Shon, Steven
American Journal of Psychiatry, ISSN 0002-953X, 08/2004, Volume 161, Issue 8, pp. 1334 - 1349
OBJECTIVE: Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general... 
DIABETES-MELLITUS | PSYCHIATRY | ANTIPSYCHOTIC-DRUGS | BODY-MASS INDEX | PROLACTIN LEVELS | RISPERIDONE | INDUCED WEIGHT-GAIN | OLANZAPINE | CORONARY-HEART-DISEASE | CLOZAPINE USE | SERUM TRIGLYCERIDE LEVELS | Clozapine - therapeutic use | Myocarditis - chemically induced | Cataract - chemically induced | Antipsychotic Agents - adverse effects | Humans | Long QT Syndrome - chemically induced | Sexual Dysfunctions, Psychological - chemically induced | Myocarditis - diagnosis | Hyperlipidemias - diagnosis | Sexual Dysfunctions, Psychological - diagnosis | Long QT Syndrome - diagnosis | Schizophrenia - diagnosis | Antipsychotic Agents - therapeutic use | Hyperprolactinemia - diagnosis | Basal Ganglia Diseases - diagnosis | Adult | Obesity - diagnosis | Weight Gain | Basal Ganglia Diseases - chemically induced | Cataract - diagnosis | Hyperprolactinemia - chemically induced | Diabetes Mellitus, Type 2 - diagnosis | Monitoring, Physiologic - methods | Diabetes Mellitus, Type 2 - chemically induced | Schizophrenia - drug therapy | Clozapine - adverse effects | Health Status | Hyperlipidemias - chemically induced | Practice Guidelines as Topic | Schizophrenia | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
by Hasan, Alkomiet and Falkai, Peter and Wobrock, Thomas and Lieberman, Jeffrey and Glenthoj, Birte and Gattaz, Wagner F and Thibaut, Florence and Möller, Hans-Jürgen and WFSBP Task Force Treatment Guideli and WFSBP Task force on Treatment Guidelines for Schizophrenia
World Journal of Biological Psychiatry, ISSN 1562-2975, 02/2013, Volume 14, Issue 1, pp. 2 - 44
Abstract These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological... 
long-term treatment | Schizophrenia | antipsychotics | evidence-based guidelines | side effects | Antipsychotics | Side effects | Evidence-based guidelines | Long-term treatment | PSYCHIATRY | RANDOMIZED CONTROLLED-TRIAL | SEVERE TARDIVE-DYSKINESIA | OLANZAPINE-TREATED PATIENTS | NEUROLEPTIC MALIGNANT SYNDROME | QUALITY-OF-LIFE | ACTING INJECTABLE RISPERIDONE | INDUCED WEIGHT-GAIN | PLACEBO-CONTROLLED TRIAL | PALIPERIDONE PALMITATE TREATMENT | NAIVE 1ST-EPISODE SCHIZOPHRENIA | Evidence-Based Medicine - methods | Hematologic Diseases - chemically induced | Antipsychotic Agents - adverse effects | Humans | Metabolic Diseases - chemically induced | Biological Psychiatry - methods | International Cooperation | Long-Term Care | Constipation - chemically induced | Central Nervous System Diseases - chemically induced | Societies, Medical | Antipsychotic Agents - therapeutic use | Cardiovascular Diseases - chemically induced | Schizophrenia - drug therapy | Clinical Medicine | Psykiatri | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Psychiatry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Consensus development conference on antipsychotic drugs and obesity and diabetes
and American Psychiatric Association and American Diabetes Association and American Association of Clinical EndocrinologistsNorth American Association for the Study of Obesity
The Journal of clinical psychiatry, ISSN 0160-6689, 2004, Volume 65, Issue 2, pp. 267 - 272
CLOZAPINE | PSYCHIATRY | GLUCOSE | SCHIZOPHRENIA | RISK | RISPERIDONE | INDUCED WEIGHT-GAIN | OLANZAPINE | MELLITUS | PSYCHOLOGY, CLINICAL | Follow-Up Studies | Humans | Diabetes Mellitus, Type 2 - epidemiology | Antipsychotic Agents - classification | Antipsychotic Agents - therapeutic use | Prediabetic State - epidemiology | Hypercholesterolemia - epidemiology | Obesity - chemically induced | Cross-Sectional Studies | Risk Assessment | Comorbidity | Diabetes Mellitus, Type 2 - prevention & control | Prediabetic State - prevention & control | Schizophrenia - epidemiology | Antipsychotic Agents - administration & dosage | Prediabetic State - chemically induced | Hypertriglyceridemia - chemically induced | Hypertriglyceridemia - epidemiology | Obesity - epidemiology | Obesity - prevention & control | Diabetes Mellitus, Type 2 - chemically induced | Hypercholesterolemia - chemically induced | Schizophrenia - drug therapy | Causality | Drug Monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
by Reynolds, Gavin P and Kirk, Shona L
Pharmacology and Therapeutics, ISSN 0163-7258, 2010, Volume 125, Issue 1, pp. 169 - 179
Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II diabetes, are significant problems for patients receiving... 
Antipsychotic drugs | Diabetes | Hypothalamus | Metabolic syndrome | Weight gain | Leptin | 1ST-EPISODE SCHIZOPHRENIA | ATYPICAL ANTIPSYCHOTICS | 5-HT2C RECEPTOR GENE | INCREASED BODY-WEIGHT | INSULIN-RESISTANCE | PHARMACOLOGY & PHARMACY | INDUCED ANOREXIA | INDUCED WEIGHT-GAIN | BETA3 SUBUNIT GENE | CLINICAL-RESPONSE | C825T POLYMORPHISM | Genetic Predisposition to Disease | Neural Pathways - drug effects | Obesity - chemically induced | Antipsychotic Agents - adverse effects | Humans | Risk Factors | Metabolic Diseases - chemically induced | Metabolic Syndrome - chemically induced | Animals | Metabolic Diseases - metabolism | Signal Transduction - drug effects | Metabolic Diseases - genetics | Neural Pathways - metabolism | Diabetes Mellitus, Type 2 - chemically induced | Complications and side effects | Histamine | Prolactin | Cardiac patients | Physiological aspects | Intermedin | Glucose | Hormones | Dextrose
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Secondary Effects of Antipsychotics: Women at Greater Risk Than Men
by Seeman, Mary V
Schizophrenia Bulletin, ISSN 0586-7614, 9/2009, Volume 35, Issue 5, pp. 937 - 948
Context: The health burden of antipsychotic medication is well known, but the disproportionate effect on women as compared with men is underappreciated.... 
Autoimmunity | Women | Blood dyscrasia | Cardiovascular risk | Antipsychotics side effects | Malignancy | Thromboembolism | RISPERIDONE PLASMA-CONCENTRATIONS | METABOLIC SYNDROME | thromboembolism | malignancy | BONE-MINERAL DENSITY | PSYCHIATRY | POSTMENOPAUSAL BREAST-CANCER | ATYPICAL ANTIPSYCHOTICS | autoimmunity | blood dyscrasia | TORSADE-DE-POINTES | antipsychotics side effects | POPULATION-BASED COHORT | BODY-MASS INDEX | cardiovascular risk | INDUCED WEIGHT-GAIN | CORONARY-HEART-DISEASE | women | Hematologic Diseases - chemically induced | Risk Assessment | Thromboembolism - chemically induced | Antipsychotic Agents - adverse effects | Humans | Male | Schizophrenic Psychology | Pregnancy | Puerperal Disorders - chemically induced | Neoplasms - chemically induced | Antipsychotic Agents - therapeutic use | Sex Factors | Female | Pregnancy Complications - chemically induced | Weight Gain - drug effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - chemically induced | Schizophrenia - drug therapy | Autoimmune Diseases - chemically induced | Drug Therapy, Combination | Infant, Newborn | Index Medicus | Regular
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Beyond White Blood Cell Monitoring: Screening in the Initial Phase of Clozapine Therapy
by Cohen, Dan and Bogers, Jan P. A. M and van Dijk, Daniel and Bakker, Bert and Schulte, Peter F. J and Dutch Clozapine Collaboration Grp
Journal of Clinical Psychiatry, ISSN 0160-6689, 10/2012, Volume 73, Issue 10, pp. 1307 - 1312
Objective: Clozapine is the preferred option for treatment-resistant schizophrenia. However, since 1975, clozapine has been known to cause agranulocytosis. In... 
UNITED-STATES | MORTALITY | 2ND-GENERATION ANTIPSYCHOTIC-DRUGS | DIABETIC-KETOACIDOSIS | PSYCHIATRY | CARDIOMYOPATHY | CHRONIC-SCHIZOPHRENIA | MYOCARDITIS | INDUCED AGRANULOCYTOSIS | PSYCHOLOGY, CLINICAL | RECEIVING CLOZAPINE | Myocarditis - chemically induced | Agranulocytosis - chemically induced | Humans | Leukocyte Count - statistics & numerical data | Mass Screening - standards | Constipation - epidemiology | Agranulocytosis - mortality | Diabetic Ketoacidosis - mortality | Myocarditis - mortality | Constipation - chemically induced | Incidence | Agranulocytosis - epidemiology | Myocarditis - epidemiology | Diabetic Ketoacidosis - epidemiology | Clozapine - adverse effects | Constipation - mortality | Diabetic Ketoacidosis - chemically induced | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study
by Morgan, Celia J. A and Muetzelfeldt, Leslie and Curran, H. Valerie
Addiction, ISSN 0965-2140, 01/2010, Volume 105, Issue 1, pp. 121 - 133
Background  `Recreational' use of ketamine is spreading rapidly among young people. In healthy individuals an acute dose of the N-methyl D-aspartate (NMDA)... 
cognition | learning and memory | ketamine | recreational use | Chronic use | NMDA receptor antagonist | dependence | depression | longitudinal | glutamate | addiction and substance abuse | Learning and memory | Recreational use | Ketamine | Longitudinal | Dependence | Depression | Cognition | Addiction and substance abuse | Glutamate | FREQUENT | DRUG-USE | INFREQUENT | PSYCHIATRY | SCHIZOPHRENIA | SUBSTANCE ABUSE | EXPERIENCES | K-HOLE | ECSTASY USERS | RECREATIONAL USERS | HEALTHY-VOLUNTEERS | WORKING-MEMORY | Memory - drug effects | Delusions - epidemiology | Follow-Up Studies | Cognition Disorders - chemically induced | Humans | Male | Memory Disorders - diagnosis | Educational Status | Statistics as Topic | Dissociative Disorders - epidemiology | Dose-Response Relationship, Drug | Dissociative Disorders - chemically induced | Ketamine - adverse effects | Psychiatric Status Rating Scales | Time Factors | Substance-Related Disorders - epidemiology | Adult | Female | Depressive Disorder - chemically induced | Depressive Disorder - epidemiology | Excitatory Amino Acid Antagonists - adverse effects | Self Medication - psychology | Cognition Disorders - psychology | Memory Disorders - epidemiology | Self Medication - statistics & numerical data | Excitatory Amino Acid Antagonists - pharmacology | Delusions - chemically induced | Neuropsychological Tests | Recognition (Psychology) - drug effects | Speech Disorders - chemically induced | Speech Disorders - epidemiology | Substance-Related Disorders - psychology | Ketamine - pharmacology | Cognition Disorders - epidemiology | Memory Disorders - chemically induced | Illegal drugs | Methyl aspartate | Substance abuse | Depression, Mental | Drug abuse | Mental depression | Cognitive ability | Mental health
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials
by Alvarez-Jimenez, Mario and Hetrick, Sarah E and Gonzalez-Blanch, Cesar and Gleeson, John F and McGorry, Patrick D
The British Journal of Psychiatry, ISSN 0007-1250, 08/2008, Volume 193, Issue 2, pp. 101 - 107
Antipsychotic-induced weight gain is a major concern in the treatment of psychosis. The efficacy of non-pharmacological interventions as well as the optimal... 
Obesity - chemically induced | Antipsychotic Agents - adverse effects | Humans | Obesity - therapy | Schizophrenia - drug therapy | Weight Gain | Randomized Controlled Trials as Topic | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Adverse effects of second-generation antipsychotics in children and adolescents: A bayesian meta-analysis
by Cohen, David and Bonnot, Olivier and Bodeau, Nicolas and Consoli, Angèle and Laurent, Claudine
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 06/2012, Volume 32, Issue 3, pp. 309 - 316
In adults, second-generation antipsychotics (SGAs) have a low frequency of extrapyramidal syndrome (EPS) and a moderate frequency of metabolic adverse effects.... 
adolescence | adverse effects | meta-analysis | second-generation antipsychotics | childhood | CLOZAPINE | PLACEBO | PSYCHIATRY | OPEN-LABEL | RISPERIDONE | BIPOLAR DISORDER | EARLY-ONSET SCHIZOPHRENIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | WEIGHT-GAIN | OLANZAPINE | ARIPIPRAZOLE | Disorders of Excessive Somnolence - chemically induced | Hyperglycemia - chemically induced | Antipsychotic Agents - adverse effects | Humans | Adolescent | Bayes Theorem | Weight Gain - drug effects | Hyperprolactinemia - chemically induced | Hyperlipidemias - chemically induced | Child | Adolescence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights